Nicola Cascavilla

List of Publications by Year
in descending order

122	5,077	136950 32	95266 68
papers	citations	h-index	g-index

123	123	123	5998
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients. European Journal of Haematology, 2022, 108, 178-189.	2.2	5
2	Validation and reference values of the EORTC QLQ-CML24 questionnaire to assess health-related quality of life in patients with chronic myeloid leukemia. Leukemia and Lymphoma, 2021, 62, 669-678.	1.3	10
3	Carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience of Rete Ematologica Pugliese (REP). Annals of Hematology, 2021, 100, 429-436.	1.8	17
4	A multicenter total therapy strategy for <i>de novo</i> adult Philadelphia chromosome positive acute lymphoblastic leukemia patients: final results of the GIMEMA LAL1509 protocol. Haematologica, 2021, 106, 1828-1838.	3.5	33
5	MATRixâ€“RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial. Lancet Haematology,the, 2021, 8, e110-e121.	4.6	54
6	Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 5	4.6	79
7	Development and Validation of a Simplified Score to Predict Early Relapse in Newly Diagnosed Multiple Myeloma in a Pooled Dataset of 2,190 Patients. Clinical Cancer Research, 2021, 27, 3695-3703.	7.0	7
8	Log reduction of leukemic cells and minimal residual disease by flow cytometry represent effective predictors of clinical outcome in elderly patients with acute myeloid leukemia. Cytometry Part B - Clinical Cytometry, 2021, 102, 26.	1.5	1
9	Pooled-analysis of Lipegfilgrastim Effectiveness and Safety Among Patients With Blood Malignancies in the Real-world Setting. Anticancer Research, 2021, 41, 347-354.	1.1	0
10	Autologous stem cell transplantation in multiple myeloma. Panminerva Medica, 2021, 62, 220-224.	0.8	7
11	Focus on Key Issues in Immune Thrombotic Thrombocytopenic Purpura: Italian Experience of Six Centers. Journal of Clinical Medicine, 2021, 10, 5702.	2.4	0
12	Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs. Haematologica, 2020, 105, 193-200.	3.5	29
13	Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy. Leukemia, 2020, 34, 488-498.	7.2	35
14	Leukemiaâ€associated immunophenotypes subdivided in â€œcategories of specificityâ€•improve the sensitivity of minimal residual disease in predicting relapse in acute myeloid leukemia. Cytometry Part B - Clinical Cytometry, 2020, 98, 216-225.	1.5	19
15	Everyâ€otherâ€day palonosetron plus aprepitant for prevention of emesis following induction chemotherapy for acute myeloid leukemia: A randomized, controlled study from the â€œRete Ematologica Pugliese†Cancer Medicine, 2020, 9, 170-178.	2.8	4
16	A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma. European Journal of Haematology, 2020, 104, 435-442.	2.2	12
17	Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study. Lancet Haematology,the, 2020, 7, e861-e873.	4.6	34
18	Brentuximab vedotin in association with bendamustine in refractory or multiple relapsed Hodgkin lymphoma. A retrospective realâ€world study. European Journal of Haematology, 2020, 104, 581-587.	2.2	10

#	Article	IF	Citations
19	Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials. Haematologica, 2020, 106, 291-294.	3.5	17
20	Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma. Leukemia and Lymphoma, 2020, 61, 1850-1859.	1.3	11
21	Real world Italian experience of pomalidomide plus low-dose dexamethasone in the relapsed and refractory myeloma setting: extended follow-up of a retrospective multicenter study by the â€˜Rete Ematologica Pugliese E Basilicataâ€™. Leukemia and Lymphoma, 2019, 60, 3565-3568.	1.3	8
22	Phase II trial with sequential clofarabine and cyclophosphamide for refractory and relapsed philadelphia-negative adult acute lymphoblastic leukemia. Results of the GIMEMA LAL 1610 protocol. Leukemia and Lymphoma, 2019, 60, 3482-3492.	1.3	3
23	Quality of Response in Acute Myeloid Leukemia: The Role of Minimal Residual Disease. Cancers, 2019, 11, 1417.	3.7	7
24	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncology, The, 2019, 20, 781-794.	10.7	254
25	Brentuximab vedotin prior to allogeneic stem cell transplantation increases survival in chemorefractory Hodgkinâ€™s lymphoma patients. Annals of Hematology, 2019, 98, 1449-1455.	1.8	8
26	Lenalidomide in Pretreated Patients with Diffuse Large Bâ€Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice. Oncologist, 2019, 24, 1246-1252.	3.7	10
27	Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the) Tj ETQq1 1 0.784314 rgBT /Ov	1.8	4
28	Timing of clopidogrel loading dose on peripheral blood endothelial progenitor cells, SDF-1Î± and neointimal hyperplasia in carotid stenting. Clinical Hemorheology and Microcirculation, 2019, 72, 23-38.	1.7	2
29	Minimal residual disease and logâ€reduction of plasma cells are associated with superior response after double autologous stem cell transplant in younger patients with multiple myeloma. Cytometry Part B - Clinical Cytometry, 2019, 96, 195-200.	1.5	11
30	Outcomes of Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Hodgkin Lymphomas: A Retrospective Multicenter Experience by the Rete Ematologica Pugliese (REP). Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 35-40.	0.4	10
31	Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis. Journal of Cancer Research and Clinical Oncology, 2018, 144, 1357-1366.	2.5	8
32	Association between proteomic profile and molecular response in chronic myeloid leukemia patients. Leukemia and Lymphoma, 2018, 59, 1016-1018.	1.3	0
33	Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma. Journal of Clinical Oncology, 2018, 36, 689-696.	1.6	107
34	A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi. Biology of Blood and Marrow Transplantation, 2018, 24, 1814-1822.	2.0	18
35	Brentuximab vedotin as salvage treatment in Hodgkin lymphoma naÃ¯ve transplant patients or failing ASCT: the real life experience of Rete Ematologica Pugliese (REP). Annals of Hematology, 2018, 97, 1817-1824.	1.8	9
36	Validation of PLASMIC score and follow-up data in a cohort of patients with suspected microangiopathies from Southern Italy. Journal of Thrombosis and Thrombolysis, 2018, 46, 174-179.	2.1	19

#	Article	IF	Citations
37	Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma. Oncotarget, 2018, 9, 23443-23450.	1.8	12
38	Ruxolitinib â€“ better prognostic impact in low-intermediate 1 risk score: evaluation of the â€˜rete ematologica puglieseâ€™ (REP) in primary and secondary myelofibrosis. Leukemia and Lymphoma, 2017, 58, 138-144.	1.3	6
39	Allogeneic Stem Cell Transplantation for Relapsed/Refractory B Cell Lymphomas: Results of a Multicenter Phase II Prospective Trial including Rituximab in the Reduced-Intensity Conditioning Regimen. Biology of Blood and Marrow Transplantation, 2017, 23, 1102-1109.	2.0	9
40	A comparative analysis of biosimilar vs. originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma: a propensityâ€score weighted multicenter approach. American Journal of Hematology, 2017, 92, E557-E559.	4.1	10
41	Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. Lancet Oncology, The, 2017, 18, 1076-1088.	10.7	100
42	Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia After Allogeneic and Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey. Clinical Infectious Diseases, 2017, 65, 1884-1896.	5.8	103
43	Onset of chronic myeloid leukemia with complex karyotype in a pregnant patient: case report and revision of literature. Therapeutics and Clinical Risk Management, 2017, Volume 13, 751-755.	2.0	4
44	Postpartum haemorrhage in a woman with essential thrombocythemia carrying calreticulin mutation. Blood Coagulation and Fibrinolysis, 2016, 27, 727-728.	1.0	1
45	Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi. Journal of Clinical Oncology, 2016, 34, 1175-1181.	1.6	94
46	Healthâ€related quality of life and burden of fatigue in patients with primary immune thrombocytopenia by phase of disease. American Journal of Hematology, 2016, 91, 995-1001.	4.1	53
47	Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustineâ€based highâ€dose chemotherapy regimen. British Journal of Haematology, 2016, 172, 111-121.	2.5	16
48	The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a â€œreal lifeâ€• retrospective multicenter experience of the Rete Ematologica Pugliese (REP). Annals of Hematology, 2016, 95, 239-244.	1.8	46
49	Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study. Drug Design, Development and Therapy, 2015, 9, 2687.	4.3	4
50	Optimal time-points for minimal residual disease monitoring change on the basis of the method used in patients with acute myeloid leukemia who underwent allogeneic stem cell transplantation: A comparison between multiparameter flow cytometry and Wilmsâ€™ tumor 1 expression. Leukemia Research, 2015, 39, 138-143.	0.8	27
51	Absolute Monocyte Count and Lymphocyte-Monocyte Ratio Predict Outcome in Nodular Sclerosis Hodgkin Lymphoma: Evaluation Based on Data From 1450 Patients. Mayo Clinic Proceedings, 2015, 90, 756-764.	3.0	39
52	Safety and Efficacy of Single-Agent Bendamustine After Failure of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin's Lymphoma: Experience With 27 Patients. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 404-408.	0.4	18
53	Azacitidine in the treatment of older patients affected by acute myeloid leukemia: A report by the Rete Ematologica Pugliese (REP). Leukemia Research, 2015, 39, 1166-1171.	0.8	5
54	Benda-BEAM High-Dose Therapy Prior to Auto-SCT Is Effective in Resistant/Relapsed DLBCL. Blood, 2015, 126, 1999-1999.	1.4	4

#	Article	IF	Citations
55	Feasibililty of Azacitidine As Bridge to Allogeneic Stem Cell Transplantation in Patients with Higher-Risk MDS or Low-Blast Count AML: Results of the BMT-AZA Multicenter Prospective Study. Blood, 2015, 126, 66-66.	1.4	2
56	Multicenter Total Therapy Gimema LAL 1509 Protocol for De Novo Adult Ph+ Acute Lymphoblastic Leukemia (ALL) Patients. Updated Results and Refined Genetic-Based Prognostic Stratification. Blood, 2015, 126, 81-81.	1.4	44
57	Bone Marrow (BM) Microenviroment Factors As Early Markers of Response in Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Treated with Nilotinib. Blood, 2015, 126, 1570-1570.	1.4	0
58	Quality of Life in Elderly Patients with Acute Myeloid Leukemia Undergoing Induction Chemotherapy. Blood, 2015, 126, 2120-2120.	1.4	0
59	Health-Related Quality of Life in Patients with Primary Immune Thrombocytopenia (pITP): Investigating Differences Amongst Newly Diagnosed, Persistent and Chronic Pitp Patients. Blood, 2015, 126, 2122-2122.	1.4	0
60	Factors affecting successful mobilization with plerixafor: an <scp>I</scp>talian prospective survey in 215 patients with multiple myeloma and lymphoma. Transfusion, 2014, 54, 331-339.	1.6	39
61	Safety and efficacy of ⁹⁰<scp>Y</scp>ttriumâ€<scp>I</scp>britumomabâ€<scp>T</scp>iuxetan for untreated follicular lymphoma patients. An <scp>I</scp>talian cooperative study. British Journal of Haematology, 2014, 164, 710-716.	2.5	31
62	Predictive role of minimal residual disease and log clearance in acute myeloid leukemia: a comparison between multiparameter flow cytometry and Wilmâ€™s tumor 1 levels. Annals of Hematology, 2014, 93, 1149-57.	1.8	26
63	Results of a Multicenter, Controlled, Randomized Clinical Trial Evaluating the Combination of Piperacillin/Tazobactam and Tigecycline in High-Risk Hematologic Patients With Cancer With Febrile Neutropenia. Journal of Clinical Oncology, 2014, 32, 1463-1471.	1.6	55
64	Bendamustine and subcutaneous alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients. Haematologica, 2014, 99, e159-e161.	3.5	4
65	<scp>CD</scp>117â€<scp>CD</scp>15 in acute myeloid leukemia: no role as <scp>LAIP</scp> in the study of minimal residual disease. European Journal of Haematology, 2013, 90, 171-174.	2.2	15
66	Minimal residual disease after allogeneic stem cell transplant: a comparison among multiparametric flow cytometry, Wilms tumor 1 expression and chimerism status (Complete chimerism versus Low) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	3.3	26
67	Cardiovascular Events and Intensity of Treatment in Polycythemia Vera. New England Journal of Medicine, 2013, 368, 22-33.	27.0	664
68	Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma. New England Journal of Medicine, 2012, 366, 1759-1769.	27.0	692
69	An Italian retrospective study on the routine clinical use of lowâ€dose alemtuzumab in relapsed/refractory chronic lymphocytic leukaemia patients. British Journal of Haematology, 2012, 156, 481-489.	2.5	17
70	Comparison between multiparameter flow cytometry and WT1-RNA quantification in monitoring minimal residual disease in acute myeloid leukemia without specific molecular targets. Leukemia Research, 2012, 36, 401-406.	0.8	36
71	Quality of life in elderly patients with essential thrombocythaemia. An Italian multicentre study. Annals of Hematology, 2012, 91, 527-532.	1.8	4
72	Cytogenetic Analysis in Patients with Newly Diagnosed Myelodysplastic Syndromes in Southern Italy. Blood, 2012, 120, 5200-5200.	1.4	1

#	Article	IF	Citations
73	Cytogenetic Analysis in Patients with Newly Diagnosed Myelodysplastic Syndromes in Southern Italy. Blood, 2012, 120, 50623-50623.	1.4	0
74	Romiplostim for chronic lymphocytic leukemia-associated immune thrombocytopenia. Leukemia and Lymphoma, 2011, 52, 701-704.	1.3	19
75	Amphotericin B Lipid Complex in the Management of Invasive Fungal Infections in Immunocompromised Patients. Clinical Drug Investigation, 2011, 31, 745-758.	2.2	18
76	Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease. Leukemia Research, 2011, 35, 363-368.	0.8	128
77	Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment. Blood, 2011, 118, 5759-5766.	1.4	34
78	Lenalidomide Restrains Motility and Overangiogenic Potential of Bone Marrow Endothelial Cells in Patients with Active Multiple Myeloma. Clinical Cancer Research, 2011, 17, 1935-1946.	7.0	75
79	Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study. Leukemia and Lymphoma, 2011, 52, 771-775.	1.3	86
80	A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide (Len) Combined with Melphalan and Prednisone Followed by Continuous Lenalidomide Maintenance (MPR-R) in Patients (Pts) â‰¥ 65 Years (Yrs) with Newly Diagnosed Multiple Myeloma (NDMM): Updated Results for Pts Aged 65â€“75 Yrs Enrolled in MM-015. Blood, 2011, 118, 475-475.	1.4	12
81	Active caspase-3 detection to evaluate apoptosis induced by Verbena officinalis essential oil and citral in chronic lymphocytic leukaemia cells. Revista Brasileira De Farmacognosia, 2011, 21, 869-873.	1.4	12
82	Chronic lymphocytic leukemiaâ€associated immune thrombocytopenia treated with rituximab: a retrospective study of 21 patients. European Journal of Haematology, 2010, 85, 502-507.	2.2	22
83	Long-Lasting Response of Chronic Lymphocytic Leukemia and Multiple Sclerosis in a Patient Treated with Oral Fludarabine Alone. Tumori, 2009, 95, 406-407.	1.1	0
84	Rituximab to treat chronic lymphoproliferative disorderâ€associated pure red cell aplasia. European Journal of Haematology, 2009, 82, 235-239.	2.2	22
85	Outcome of 122 pregnancies in essential thrombocythemia patients: A report from the Italian registry. American Journal of Hematology, 2009, 84, 636-640.	4.1	75
86	Increased serum bilirubin level without jaundice in patients with monoclonal gammopathy. Leukemia and Lymphoma, 2009, 50, 1392-1394.	1.3	8
87	Corticoisteroid-Induced Apoptosis in Hematological Malignancies. Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry, 2009, 8, 38-46.	1.1	1
88	Attenuated doses of rituximab for the treatment of adults with autoimmune cytopenias. American Journal of Hematology, 2008, 83, 686-687.	4.1	3
89	Gemtuzumab ozogamicin as maintenance therapy after autologous stem cell transplantation in elderly patients with acute myeloid leukaemia. British Journal of Haematology, 2008, 142, 852-853.	2.5	5
90	Schnitzler syndrome. British Journal of Haematology, 2008, 143, 152-152.	2.5	2

#	Article	IF	Citations
91	Combined fine needle cytology and flow cytometry immunophenotyping for diagnosis of lymphoid disorders. Leukemia and Lymphoma, 2008, 49, 1212-1213.	1.3	0
92	Monoclonal Antibodies: New Therapeutic Agents for Autoimmune Hemolytic Anemia?. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2008, 8, 62-68.	1.2	10
93	Symptomatic Venous Thromboembolism and Thrombophilic Status in Adult Acute Leukemia: A Single-Center Experience of 114 Patients at Diagnosis. Acta Haematologica, 2007, 117, 215-220.	1.4	29
94	Chronic lymphocytic leukemia-associated autoimmune hemolytic anemia. Leukemia and Lymphoma, 2007, 48, 1072-1080.	1.3	30
95	Rituximab for warm-type idiopathic autoimmune hemolytic anemia: a retrospective study of 11 adult patients. European Journal of Haematology, 2007, 79, 53-58.	2.2	71
96	Adult T-cell acute lymphoblastic leukemia: biologic profile at presentation and correlation with response to induction treatment in patients enrolled in the GIMEMA LAL 0496 protocol. Blood, 2006, 107, 473-479.	1.4	109
97	Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide. Leukemia Research, 2006, 30, 283-285.	0.8	17
98	A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol. Blood, 2005, 105, 3434-3441.	1.4	178
99	The Significance of Minimal Residual Disease in Stem Cell Grafts and the Role of Purging: Is It Better to Purge in vivo or in vitro?. Acta Haematologica, 2005, 114, 206-213.	1.4	8
100	Heterogeneity of Response to Imatinib-Mesylate (Glivec) in Patients with Hypereosinophilic Syndrome: Implications for Dosing and Pathogenesis. Leukemia and Lymphoma, 2004, 45, 1219-1222.	1.3	21
101	Short progression-free survival in myeloma patients receiving rituximab as maintenance therapy after autologous transplantation. British Journal of Haematology, 2003, 123, 746-747.	2.5	22
102	Pamidronate Reduces Skeletal Events but does not Improve Progression-free Survival in Early-stage Untreated Myeloma: Results of a Randomized Trial. Leukemia and Lymphoma, 2003, 44, 1545-1548.	1.3	43
103	Pamidronate Reduces Skeletal Events but does not Improve Progression-free Survival in Early-stage Untreated Myeloma: Results of a Randomized Trial. Leukemia and Lymphoma, 2003, 44, 1545-1548.	1.3	35
104	Usefulness of RA and RO Isoforms of Common Leukocyte Antigen (CD45) for Early Distinction Between Normal and Abnormal Promyelocytes. Leukemia and Lymphoma, 2002, 43, 1823-1825.	1.3	6
105	Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood, 2002, 99, 863-871.	1.4	325
106	Immunophenotypic Profile of AC133-Positive Cells in Bone Marrow, Mobilized Peripheral Blood and Umbilical Cord Blood. Leukemia and Lymphoma, 2002, 43, 869-873.	1.3	12
107	MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. Blood, 2002, 100, 974-981.	1.4	99
108	Is the scoring system an effective clinico-biological tool in myeloid antigen positive adult acute lymphoblastic leukemia? Results of a long-term study. The Hematology Journal, 2002, 3, 251-258.	1.4	3

#	Article	IF	Citations
109	Treatment of â€œPoor Riskâ€•Acute Myeloid Leukemia with Fludarabine, Cytarabine and G-CSF (Flag) Tj ETQq1 1 0.784314 rgBT /Overlo	1.3	29
110	CD38 Expression Correlates with Adverse Biological Features and Predicts Poor Clinical Outcome in B-Cell Chronic Lymphocytic Leukemia. Leukemia and Lymphoma, 2001, 42, 109-114.	1.3	76
111	Morphologically Typical and Atypical B-Cell Chronic Lymphocytic Leukemias Display a Different Pattern of Surface Antigenic Density. Leukemia and Lymphoma, 2001, 42, 649-654.	1.3	21
112	Quantitative flow cytometry for the differential diagnosis of leukemic B-cell chronic lymphoproliferative disorders. American Journal of Hematology, 2000, 64, 275-281.	4.1	91
113	Minimally Differentiated Acute Myeloid Leukemia (AML M0): Clinico-Biological Findings of 29 Cases. Leukemia and Lymphoma, 2000, 37, 105-113.	1.3	24
114	Inability of Activated Cord Blood T Lymphocytes to Perform Th1-like and Th2-like Responses: Implications for Transplantation. Journal of Hematotherapy and Stem Cell Research, 1999, 8, 381-385.	1.8	16
115	Clinicoâ€prognostic implications of simultaneous increased serum levels of soluble CD23 and Î²₂â€microglobulin in Bâ€cell chronic lymphocytic leukemia. European Journal of Haematology, 1999, 62, 117-122.	2.2	75
116	Predictive parameters for mobilized peripheral blood CD34+ progenitor cell collection in patients with hematological malignancies. , 1998, 58, 255-262.		24
117	Are â€œEarlyâ€•and â€œLateâ€•T-Acute Lymphoblastic Leukemias Different Diseases? A Single Center Study of 34 Patients. Leukemia and Lymphoma, 1996, 21, 437-442.	1.3	6
118	SPONTANEOUS REMISSION IN ACUTE MYELOID LEUKAEMIA: A ROLE FOR ENDOGENOUS PRODUCTIONOF TUMOUR NECROSIS FACTOR AND INTERLEUKINâ€2?. British Journal of Haematology, 1994, 87, 879-880.	2.5	41
119	Immunophenotype of Acute Lymphoblastic Leukemia Cells: The Experience of the Italian Cooperative Group (Gimema). Leukemia and Lymphoma, 1993, 9, 221-228.	1.3	17
120	Clinical Relevance of Immunocytochemical Detection of Multidrug-Resistance-Associated P-Glycoprotein in Hematologic Malignancies. Tumori, 1990, 76, 353-359.	1.1	21
121	Significance and limits of cerebrospinal fluid beta-2-microglobulin measurement in course of acute lymphoblastic leukemia. American Journal of Hematology, 1988, 28, 213-218.	4.1	4
122	Serum Beta2-Microglobulin in Malignant Lymphoproliferative Disorders. Tumori, 1988, 74, 129-135.	1.1	17